These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17371534)

  • 1. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank.
    Peissig P; Sirohi E; Berg RL; Brown-Switzer C; Ghebranious N; McCarty CA; Wilke RA
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):286-8. PubMed ID: 17371534
    [No Abstract]   [Full Text] [Related]  

  • 2. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin.
    Mikhailidis DP; Wierzbicki AS
    Curr Med Res Opin; 2000; 16(2):139-46. PubMed ID: 10893658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository.
    Wilke RA; Berg RL; Linneman JG; Zhao C; McCarty CA; Krauss RM
    Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):354-9. PubMed ID: 18834356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of low doses of simvastatin versus atorvastatin: resolving conflicting evidence.
    Chong C; Kelly S; Bradley M
    Clin Ther; 2002 Feb; 24(2):325-8. PubMed ID: 11911562
    [No Abstract]   [Full Text] [Related]  

  • 6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
    Kastelein JJ; Isaacsohn JL; Ose L; Hunninghake DB; Frohlich J; Davidson MH; Habib R; Dujovne CA; Crouse JR; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB
    Am J Cardiol; 2000 Jul; 86(2):221-3. PubMed ID: 10913488
    [No Abstract]   [Full Text] [Related]  

  • 10. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease.
    Foody JM; Joyce AT; Jeffers BW; Liu LZ; Benner JS
    Diabetes Res Clin Pract; 2008 Oct; 82(1):e13-5. PubMed ID: 18774618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
    Sathyapalan T; Atkin SL; Kilpatrick ES
    Diabet Med; 2008 Aug; 25(8):909-15. PubMed ID: 18959603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
    Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of atorvastatin on LDL & hs-CRP in a selected Thai population.
    Boonbaichaiyapruck S; Cheepudomwit S; Panjavenin P; Suthichaiyakul T; Moleelerkpoom W; Benjanuwatra T; Sukanandachai B; Buakhamsri A
    J Med Assoc Thai; 2008 Aug; 91(8):1189-95. PubMed ID: 18788689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
    Constance C; Westphal S; Chung N; Lund M; McCrary Sisk C; Johnson-Levonas AO; Massaad R; Allen C
    Diabetes Obes Metab; 2007 Jul; 9(4):575-84. PubMed ID: 17451425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
    Rogers SL; Magliano DJ; Levison DB; Webb K; Clarke PJ; Grobler MP; Liew D
    Clin Ther; 2007 Feb; 29(2):242-52. PubMed ID: 17472817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin.
    Nováková L; Vlcková H; Satínský D; Sadílek P; Solichová D; Bláha M; Bláha V; Solich P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):2093-103. PubMed ID: 19540175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.